2020年4月10日 · An ultra-purified, high-concentration galacto-oligosaccharide, RP-G28, is being developed as a treatment for patients with LI. The efficacy and safety of RP-G28 in reducing symptoms of lactose intolerance were assessed in a blinded, randomized, placebo-controlled trial.

An ultra-purified, high-concentration galacto-oligosaccharide, RP-G28, is being developed as a treatment for patients with LI. The efficacy and safety of RP-G28 in reducing symptoms of lactose intolerance were assessed in a blinded, randomized, placebo-controlled trial.

2020年4月10日 · RP-G28, an ultra-purified, high-concentration (>95%) galacto-oligosaccharide, has been evaluated in a Phase 2a study in 85 patients [2]. RP-G28 reduced abdominal pain in 50 percent of patients after treatment and 30 days post-treatment (p = 0.019).

2017年1月7日 · A randomized, double-blind, multisite placebo-controlled trial conducted in human subjects demonstrated that administration of a highly purified (>95%) short-chain galactooligosaccharide (GOS), designated "RP-G28," significantly improved clinical outcomes for lactose digestion and tolerance.

A novel galacto-oligosaccharide (RP-G28) shifts the human gut microbiota by altering the relative abundance of specific bacteria. These changes remove undigested lactose from the gut, thus reducing the gas production and water secretion that produce LI symptoms.

RP-G28 is novel galacto-oligosaccharide (GOS) being investigated to improve lactose digestion and the symptoms of lactose intolerance in affected patients. A randomized, double-blind, parallel group, placebo-controlled study was conducted at 2 sites in the United States. RP-G28 or placebo was administered to 85 patients with LI for 35 days.

2018年3月15日 · 通过调节肠道微生物群进行胃肠道疾病创新疗法开发的美国制药公司 Ritter 公布称，其主要在研药物 RP-G28 在 377 例乳糖不耐受患者的 2b 期研究中，达到了促进肠道微生物群有益适应的作用。

2018年7月13日 · 一项评估 RP-G28 在乳糖不耐症患者中的疗效、持久性、安全性和耐受性的 3 期、多中心、随机、双盲、安慰剂对照、平行组研究. 这是一项在美国 (US) 进行的多中心、随机、双盲、安慰剂对照、平行组研究，旨在评估 RP-G28 与安慰剂相比对减轻乳糖不耐受相关症状的疗效。 本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。 研究人员寻找符合特定描述的人，称为资格标准。 这些标准的一些例子是一个人的一般健康状况或先前 …

2013年12月13日 · RP-G28 is novel galacto-oligosaccharide (GOS) being investigated to improve lactose digestion and the symptoms of lactose intolerance in affected patients. Methods: A randomized, double-blind, parallel group, placebo-controlled study was conducted at 2 …

2020年4月10日 · 正在开发一种超纯化，高浓度的低聚半乳糖RP-G28，以治疗LI患者。 在一项盲法，随机，安慰剂对照试验中评估了RP-G28在减轻乳糖不耐症症状方面的功效和安全性。 方法：在这项多临床，双盲，安慰剂对照试验中，将377例LI患者随机分为两组，分别口服两种剂量的RP-G28或安慰剂，共30天。 在基线和第31天进行LI测试和症状评估。 主要终点是在第31天，LI综合评分降低≥4分或得分为零。 自愿采乳和采乳量以及总体结局指标评估了患者在治疗前和治 …